Was it something they said?
Shares of Thoratec Corp. (NSDQ:THOR) plunged on Wall Street Friday, despite solid second quarter earnings results that saw the company boost its bottom line by 765 percent.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
Was it something they said?
Shares of Thoratec Corp. (NSDQ:THOR) plunged on Wall Street Friday, despite solid second quarter earnings results that saw the company boost its bottom line by 765 percent.
Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) is once again feeling the effects of sluggish sales of Boston Scientific Corp,’s (NYSE:BSX) Taxus coronary stent systems.
The Vancouver-based company makes paclitaxel, the drug used in the stent’s coating that is designed to reduce restenosis or the re-narrowing of blood vessels after stents are implanted. Angiotech reaps around 6 percent of the net sales of Taxus stents worldwide in royalties for BSX’s use of its product.
Covidien Plc. (NYSE:COV) won an appeal of a trial judge’s decision to back Becton Dickinson and Company’s (NYSE:BDX) patent infringement claim.
The U.S. Court of Appeals for the Federal Circuit in Washington on Thursday tossed the $58 million damage award against the Mansfield, Mass. based medical products conglomerate, formerly Tyco Healthcare, over safety syringes.
Abbie Celniker, the CEO of Cambridge, Mass.-based Taligen Therapeutics, is the newest member on the board of directors at the Massachusetts Life Sciences Center.
Massachusetts Governor Deval Patrick made his appointment of the former Novartis Global Head of Biologics final on June 29.
Charles River Laboratories International Inc. (NYSE:CRL) will leave WuXi PharmaTech (Cayman) Inc. (NYSE:WX) at the altar and take its $1.6 billion dowry with it, after failing to convince shareholders that the union was in the best interest of the company.
The Wilmington, Mass.-based contract research organization said it has agreed to terminate the proposed deal and will pay a $30 million break-up fee.
Insulet Corp. (Nasdaq:PODD) is moving into its second decade as a business looking at new markets for its OmniPod insulin infusion device, improving sales, better terms on its long-term debt and a little extra cash.
But it’s still fighting a problem that’s as old as the company: Net losses typically running out to eight digits.
The tax man took a bite out of Becton, Dickinson and Company’s (NYSE:BDX) bottom line during the third quarter.
The Franklin Lakes, N.J.-based medical device and diagnostic kit-maker reported $306.9 million in net income, or $1.29 per diluted share, on $1.88 billion in sales during the three months ended June 30, a 10 percent slide from the $341 million, or $1.39 per diluted share profit on sales of $1.82 billion during the same period last year.
The U.S. Food & Drug Administration said it is requiring nine medical device companies to conduct postmarket analysis on a connection between needless connectors and higher rates of blood stream infections.
In a notice posted on the Centers for Devices and Radiological Health web site, officials said that the agency is “aware of information that raises concerns about the safety of positive displacement needleless connectors.”
Medtronic Inc. (NYSE:MDT) launched a global, randomized clinical trial to see if spinal cord stimulation can slow the progression of heart failure.
It’s an intriguing collaboration between two of the Fridley, Minn.-based company’s major markets—cardiac rhythm management and neuromodulation. Under CEO Bill Hawkins’ "One Medtronic" strategy, the company is seeking to drive greater collaboration and synergies from the company’s once disparate business units.
Zoll Medical Corp. (NSDQ:ZOLL) continues to have a rebound year in 2010, posting a 285 percent increase in its bottom line during the three month period ended on July 4.
The Chelmsford, Mass-based resuscitation products maker reported revenues of $111.3 million in its third quarter, compared with $95 million during the same period last year, a 17 percent increase overall. The brisk sales helped the company post a $5.7 million profit, a 285 percent increase from the $1.5 million in net income the company posted for the same period last year.
Palomar Medical Technologies Inc. (NSDQ:PMTI) Q2 losses surged some 600 percent as it invested heavily in infrastructure costs.
The cosmetic laser surgery equipment-maker reported $1.7 million in net losses, or 9 cents per diluted share, on $15.6 million in sales during the three months ended June 30. A dramatic increase compared to a net loss of $243,922, at 1 cent per diluted share, on revenue of $15.0 million during the same period last year.